This guide is educational, not a recommendation to use SS-31 or elamipretide. It contains no dosing or treatment instructions. Sources checked November 15, 2026. No clinician review is claimed.
Elamipretide has genuine human trials and an FDA-approved product for a specific rare disease. Neither fact establishes that a product labeled SS-31 reliably improves unexplained fatigue, everyday energy or athletic performance. The evidence includes an encouraging small study, a larger negative trial and laboratory measurements that should not be mistaken for feeling or functioning better.
The useful question is not simply whether this peptide “helps mitochondria.” It is which preparation was studied, in whom, by which route, and whether the measured outcome matches the benefit being claimed.
SS-31, elamipretide and Forzinity are related names, not interchangeable product claims
Clinical research has used SS-31 and MTP-131 as names for elamipretide. The registered Barth-syndrome trial protocol explicitly lists these names together. That helps connect papers using different terminology; it does not authenticate the contents of every product carrying one of those names. Original trial protocol
Forzinity is the named prescription elamipretide product. Its current US label specifies improvement of muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. It is a subcutaneous formulation. This is a defined indication, not an approval for general fatigue, anti-aging or fitness. Current prescribing information
The distinction works in both directions. Calling elamipretide an entirely unapproved research substance ignores the approved product. Calling every SS-31 preparation approved because Forzinity exists ignores the product and indication boundaries.
What accelerated approval does and does not establish
FDA granted Forzinity accelerated approval on September 19, 2025. The agency based the decision on improved knee-extensor muscle strength, considered reasonably likely to predict a benefit patients experience. FDA required a randomized, double-blind, placebo-controlled post-approval trial to confirm that the strength changes translate into clinical benefit. FDA approval announcement
Accelerated approval is real approval, not merely permission to conduct research. It also retains an important uncertainty about the relationship between the intermediate measurement and the expected benefit. Describing it as proof that the medicine resolves fatigue would change both the endpoint and the scope of the decision.
A rare-disease indication cannot be expanded simply because people outside that disease also report tiredness. Sharing a symptom does not mean sharing the trial population or the biological problem that defined eligibility.
The Barth study had a randomized phase and an open-label extension
The original Barth trial enrolled 12 participants in a randomized, blinded crossover comparison. During that phase, elamipretide did not significantly improve either primary endpoint: six-minute walking distance or the disease-specific fatigue score. The subsequent open-label extension reported improvements, but everyone in that extension knew they were receiving active treatment. Original Barth trial
The current label locates the observed knee-extensor strength increases in the extension, not the randomized phase. Prescribing information, clinical studies
These phases answer different questions. A comparison against placebo is not equivalent to a change from someone's own earlier measurement. Longer follow-up can reveal useful information, but removing the concurrent blinded comparison also makes changes harder to attribute confidently.
The approval and the initial randomized findings therefore should be described together, not treated as competing slogans. The regulatory decision addressed a specific strength endpoint and population; the randomized phase did not demonstrate the walk and fatigue benefits it initially tested.
A small mitochondrial-myopathy trial produced an encouraging fatigue signal
MMPOWER-2 enrolled 30 adults with genetically confirmed primary mitochondrial myopathy, or PMM. In this double-blind crossover trial, participants received subcutaneous elamipretide and placebo in separate four-week periods. The primary walking-distance comparison favored elamipretide numerically but did not reach statistical significance.
Several patient-reported fatigue measures favored treatment. The authors described these secondary findings as nominally significant and as a signal supporting a larger trial. Other functional assessments did not significantly improve. MMPOWER-2 original report
This is why some accounts describe positive fatigue research. That evidence should not be erased. But a small study's encouraging secondary findings are not the same as a replicated benefit, particularly once a larger trial has directly tested the question.
The larger PMM trial did not confirm walking or fatigue benefits
MMPOWER-3 randomized 218 participants with genetically confirmed PMM to subcutaneous elamipretide or placebo for 24 weeks. Neither primary endpoint, six-minute walking distance nor the PMM symptom assessment's total fatigue score, showed a statistically significant treatment advantage. A favorable walking result in a nuclear-DNA subgroup was identified in a post hoc analysis; it did not establish a fatigue benefit or replace the overall trial result. MMPOWER-3 original report
A null trial does not prove that every future formulation or carefully selected subgroup must fail. It does mean that the proposed benefit was not demonstrated in the study's overall population. Exploratory findings can guide another study without becoming a dependable promise for readers.
PMM is a defined group of genetic disorders. This trial was not a study of anyone who felt tired, had a difficult training week or wanted more energy. Its negative result should remain specific, just as its exploratory positive finding should.
An ATP measurement is not a fatigue result
A randomized study in 39 adults aged 60–85 selected for low mitochondrial function tested an intravenous elamipretide infusion. Researchers measured skeletal-muscle ATP-production capacity. The acute percentage-change analysis favored elamipretide, while the absolute-change comparison narrowly missed conventional statistical significance. The change in ATP capacity did not differ between groups at the later seven-day assessment.
The prespecified hand-muscle fatigue-resistance analysis did not show a significant treatment effect; additional post hoc analyses were more favorable. Original older-adult study
ATP is involved in cellular energy transfer, but a measured change in production capacity is not a direct measurement of a person's overall energy, endurance or wellbeing. Nor does an acute intravenous experiment validate repeated subcutaneous use for healthy performance. Route, selection criteria and endpoint all remain part of the result.
Do feeling tired, energized or unchanged reveal mitochondrial repair?
Not by themselves. A change noticed after exposure does not isolate its cause. Sleep, illness, activity, expectations and other substances can change at the same time. A personal account can identify a question; it cannot establish that an intervention repaired mitochondria or caused a later improvement.
The same limit applies to explanations that worsening fatigue means a beneficial adjustment is underway. The trials reviewed here do not establish that rule. Lack of an immediate sensation is not proof of hidden benefit either. An explanation needs evidence that measures the claimed outcome, rather than interpreting every possible experience as confirmation.
Safety and product identity still matter
The Forzinity label identifies injection-site reactions as the most common adverse reactions and warns about serious hypersensitivity. That is not a complete safety description for every person or formulation. An approved medicine is not risk-free, and its labeling cannot validate the quality of an unrelated product using a research name. Prescribing information, safety sections
This is a bounded review of selected original trials and current US product information, not an exhaustive review of every indication or ongoing study. The evidence supports a precise conclusion: elamipretide's specific approval, early fatigue signals and mitochondrial measurements do not establish a general-purpose treatment for fatigue or a performance benefit in healthy people.